First gene therapy to limp onto EU market
This article was originally published in Scrip
The European Commission has followed the CHMP's recommendation and approved UniQure's gene therapy Glybera (alipogene tiparvovec) in the European Union, but the company is not leaping out of the starting blocks. It says it will begin the commercial roll-out in the second half of 2013.
You may also be interested in...
White Flag Raised: UniQure Gives Up On Glybera, But Not Gene Therapies
UniQure will not seek marketing authorization renewal for Glybera in the EU before it expires in October, but the company does not see the product's commercial failure as a sign that the market won't accept gene therapies or their high price tags.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 9: The Natural Environment
Improving human health is the raison d’etre of the biopharma sector. But what can the industry do to safeguard and improve the health of Planet Earth? Executives shared their thoughts with Scrip.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.